Background and Aims: Often a cause for chronic non-specific diarrhea (≥ ... A group of patients with symptoms of reflux oesophagitis were used as control subjects. The clinical utility of a ...
UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with ...
2024 — A study of nearly 2,000 former NFL players shows one-third believe that they have chronic traumatic encephalopathy (CTE). Those individuals were more likely to report cognitive symptoms ...
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved ...